ZNTL PE Ratio & Valuation,Is ZNTL Overvalued

ZNTL Relative Valuation

ZNTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZNTL is overvalued; if below, it's undervalued.

Historical Valuation

Zentalis Pharmaceuticals Inc (ZNTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.54. The fair price of Zentalis Pharmaceuticals Inc (ZNTL) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.39

Fair

-0.80

0.88

EV/EBITDA

Zentalis Pharmaceuticals Inc. (ZNTL) has a current EV/EBITDA of 0.88. The 5-year average EV/EBITDA is -3.57. The thresholds are as follows: Strongly Undervalued below -11.29, Undervalued between -11.29 and -7.43, Fairly Valued between 0.29 and -7.43, Overvalued between 0.29 and 4.15, and Strongly Overvalued above 4.15. The current Forward EV/EBITDA of 0.88 falls within the Overvalued range.

0.94

EV/EBIT

Zentalis Pharmaceuticals Inc. (ZNTL) has a current EV/EBIT of 0.94. The 5-year average EV/EBIT is -3.59. The thresholds are as follows: Strongly Undervalued below -11.43, Undervalued between -11.43 and -7.51, Fairly Valued between 0.34 and -7.51, Overvalued between 0.34 and 4.26, and Strongly Overvalued above 4.26. The current Forward EV/EBIT of 0.94 falls within the Overvalued range.

0.00

Zentalis Pharmaceuticals Inc. (ZNTL) has a current PS of 0.00. The 5-year average PS is 232.92. The thresholds are as follows: Strongly Undervalued below -1838.54, Undervalued between -1838.54 and -802.81, Fairly Valued between 1268.65 and -802.81, Overvalued between 1268.65 and 2304.38, and Strongly Overvalued above 2304.38. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.58

P/OCF

Zentalis Pharmaceuticals Inc. (ZNTL) has a current P/OCF of -1.58. The 5-year average P/OCF is -5.85. The thresholds are as follows: Strongly Undervalued below -15.52, Undervalued between -15.52 and -10.68, Fairly Valued between -1.01 and -10.68, Overvalued between -1.01 and 3.82, and Strongly Overvalued above 3.82. The current Forward P/OCF of -1.58 falls within the Historic Trend Line -Fairly Valued range.

-0.77

P/FCF

Zentalis Pharmaceuticals Inc. (ZNTL) has a current P/FCF of -0.77. The 5-year average P/FCF is -5.55. The thresholds are as follows: Strongly Undervalued below -14.00, Undervalued between -14.00 and -9.78, Fairly Valued between -1.33 and -9.78, Overvalued between -1.33 and 2.89, and Strongly Overvalued above 2.89. The current Forward P/FCF of -0.77 falls within the Overvalued range.

Zentalis Pharmaceuticals Inc (ZNTL) has a current Price-to-Book (P/B) ratio of 0.40. Compared to its 3-year average P/B ratio of 1.61 , the current P/B ratio is approximately -75.10% higher. Relative to its 5-year average P/B ratio of 3.53, the current P/B ratio is about -88.67% higher. Zentalis Pharmaceuticals Inc (ZNTL) has a Forward Free Cash Flow (FCF) yield of approximately -132.48%. Compared to its 3-year average FCF yield of -64.62%, the current FCF yield is approximately 105.01% lower. Relative to its 5-year average FCF yield of -41.61% , the current FCF yield is about 218.36% lower.

0.40

P/B

Median3y

1.61

Median5y

3.53

-132.48

FCF Yield

Median3y

-64.62

Median5y

-41.61

Competitors Valuation Multiple

The average P/S ratio for ZNTL's competitors is 0.00, providing a benchmark for relative valuation. Zentalis Pharmaceuticals Inc Corp (ZNTL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ZNTL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ZNTL in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Zentalis Pharmaceuticals Inc (ZNTL) currently overvalued or undervalued?

What is Zentalis Pharmaceuticals Inc (ZNTL) fair value?

ZNTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Zentalis Pharmaceuticals Inc (ZNTL) is between NaN to NaN according to relative valuation methord.

How does ZNTL's valuation metrics compare to the industry average?

What is the current P/B ratio for Zentalis Pharmaceuticals Inc (ZNTL) as of Dec 16 2025?

As of Dec 16 2025, Zentalis Pharmaceuticals Inc (ZNTL) has a P/B ratio of 0.40. This indicates that the market values ZNTL at 0.40 times its book value.

What is the current FCF Yield for Zentalis Pharmaceuticals Inc (ZNTL) as of Dec 16 2025?

As of Dec 16 2025, Zentalis Pharmaceuticals Inc (ZNTL) has a FCF Yield of -132.48%. This means that for every dollar of Zentalis Pharmaceuticals Inc’s market capitalization, the company generates -132.48 cents in free cash flow.

What is the current Forward P/E ratio for Zentalis Pharmaceuticals Inc (ZNTL) as of Dec 16 2025?

As of Dec 16 2025, Zentalis Pharmaceuticals Inc (ZNTL) has a Forward P/E ratio of -0.80. This means the market is willing to pay $-0.80 for every dollar of Zentalis Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zentalis Pharmaceuticals Inc (ZNTL) as of Dec 16 2025?

As of Dec 16 2025, Zentalis Pharmaceuticals Inc (ZNTL) has a Forward P/S ratio of 0.00. This means the market is valuing ZNTL at $0.00 for every dollar of expected revenue over the next 12 months.

ZNTL Valuation